Roivant Sciences

ROIV

Market cap $16.2B

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

The Goldman Sachs Mid Cap Growth Fund underperformed its benchmark, the Russell Midcap Growth Index (net), during the quarter. United Rentals, Inc. released a positive quarterly earnings report, surpassing earnings expectations and raising future guidance, which the street responded favorably toward. Roivant Sciences Ltd.'s stock price soared during the period following the release of positive data for a drug it is developing that aims to treat inflammatory autoimmune diseases.

Roivant Sciences Ltd. (ROIV) Analyst/Investor Day Transcript

BASEL, Switzerland and LONDON and NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today is hosting an Investor Day in New York City. Roivant leadership will highlight key pipeline updates and provide an update on the Company's strategy for long-term value creation.

Roivant Sciences Ltd. ( ROIV ) Jefferies London Healthcare Conference 2025 November 18, 2025 12:00 PM EST Company Participants Matthew Gline - CEO & Director Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Presentation Yuchen Ding Jefferies LLC, Research Division Good afternoon.

ROIV's holding-company model with its Vants continues creating shareholder value. They then recycle M&A and partnership proceeds into late-stage assets. ROIV focuses on autoimmune and rare-disease drug programs. Recent promising Phase 3 data for DM with Brepocitinib have helped the stock appreciate. Brepocitinib could tap into a sizeable TAM over time, and its NDA filing for DM is expected by 1H2026. Plus, it can target NIU and CS.

Roivant Sciences Ltd. ( ROIV ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 8:00 AM EST Company Participants Richard Pulik - Chief Financial Officer Conference Call Participants Yatin Suneja - Guggenheim Securities, LLC, Research Division Presentation Yatin Suneja Guggenheim Securities, LLC, Research Division All right.

Roivant Sciences Ltd. ( ROIV ) Q2 2026 Earnings Call November 10, 2025 8:00 AM EST Company Participants Stephanie Lee Griffin - Chief Operating Officer of Roivant Platforms Matthew Gline - CEO & Director Conference Call Participants David Risinger - Leerink Partners LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Samantha Semenkow - Citigroup Inc., Research Division Yaron Werber - TD Cowen, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Yuchen Ding - Jefferies LLC, Research Division Dominic Risso-Gill Douglas Tsao - H.C.

Roivant Sciences Ltd. (ROIV) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27.